SciELO - Scientific Electronic Library Online

 
vol.60 número2Efecto del Seguro Popular de Salud sobre los gastos catastróficos y empobrecedores en México, 2004-2012Cepas E-ESKAPE multidrogorresistentes aisladas en hemocultivos de pacientes con cáncer índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Salud Pública de México

versión impresa ISSN 0036-3634

Resumen

MOHAR-BETANCOURT, Alejandro et al. Prognostic factors in patients with breast cáncer and brain metastasis as the first site of recurrence. Salud pública Méx [online]. 2018, vol.60, n.2, pp.141-150. ISSN 0036-3634.  https://doi.org/10.21149/9082.

Objective:

To evaluate the prognostic factors (clinical-pathological characteristics and treatments) in patients with breast cancer and metastasis to central nervous system (CNS) as the first site of the disease.

Materials and methods:

Kaplan-Meier method and life tables were used to estimate overall survival time over a retrospective cohort of 125 breast cancer patients treated at the Instituto Nacional de Cancerología (INCan) during 2007-2015, who presented metastasis to the CNS as the first site of extension of the disease. The cox proportional hazards model was used to determine the prognosis factors.

Result:

The median overall survival time was 14.2 months (IC95%: 11.83-26.93). Patients with triple negative (TN), according to inmunohistochemistry analysis classification, had lower survival times (p=0.0004) and had a risk of dying two times (p=0.037) higher than patients with a different immunophenotype (HR: 2.77. 95%CI: 1.10-6.99). The degree of intermediate SBR increases the risk of dying in patients with metastasis (HR 2.76, 95% CI: 1.17-6.51).

Conclusion:

CNS metastasis continues to be a poor prognostic factor that reduces survival and affects quality of life. It is recommended to monitor the early presence of clinical neurological manifestations during follow-up for prompt treatment. TN patients have worse prognosis and HER2+ a better control.

Palabras llave : neoplasm metastasis; breast neoplasms; central nervous system; prognosis.

        · resumen en Español     · texto en Español     · Español ( pdf )